53 related articles for article (PubMed ID: 11156222)
1. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation.
Rasmussen LJH; Petersen JEV; Eugen-Olsen J
Front Immunol; 2021; 12():780641. PubMed ID: 34925360
[TBL] [Abstract][Full Text] [Related]
2. Integrative analysis of mRNA and miRNA expression profiles reveals seven potential diagnostic biomarkers for non‑small cell lung cancer.
Zhang J; Li D; Zhang Y; Ding Z; Zheng Y; Chen S; Wan Y
Oncol Rep; 2020 Jan; 43(1):99-112. PubMed ID: 31746439
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatic identification of key genes and analysis of prognostic values in clear cell renal cell carcinoma.
Luo T; Chen X; Zeng S; Guan B; Hu B; Meng Y; Liu F; Wong T; Lu Y; Yun C; Hocher B; Yin L
Oncol Lett; 2018 Aug; 16(2):1747-1757. PubMed ID: 30008862
[TBL] [Abstract][Full Text] [Related]
4.
Terashima M; Ichikawa W; Ochiai A; Kitada K; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M;
Oncotarget; 2017 Aug; 8(34):57574-57582. PubMed ID: 28915696
[TBL] [Abstract][Full Text] [Related]
5. Recurrent oral cancer: current and emerging therapeutic approaches.
da Silva SD; Hier M; Mlynarek A; Kowalski LP; Alaoui-Jamali MA
Front Pharmacol; 2012; 3():149. PubMed ID: 23060791
[TBL] [Abstract][Full Text] [Related]
6. Cancer cell cytotoxicities of 1-(4-substitutedbenzoyl)-4-(4-chlorobenzhydryl)piperazine derivatives.
Yarim M; Koksal M; Durmaz I; Atalay R
Int J Mol Sci; 2012; 13(7):8071-8085. PubMed ID: 22942690
[TBL] [Abstract][Full Text] [Related]
7. Different spontaneous pulmonary metastasis inhibitions against lewis lung carcinoma in mice by bisdioxopiperazine compounds of different treatment schedules.
Lu DY; Wu FG; Zhen ZM; Lu TR; Wu HY; Che JY; Xu B
Sci Pharm; 2010; 78(1):13-20. PubMed ID: 21179367
[TBL] [Abstract][Full Text] [Related]
8. Absorption, distribution and excretion of ¹⁴C-probimane in mice bearing lewis lung carcinoma.
Lu DY; Chen RT; Lu TR; Wu HY; Qu RX; Che JY; Xu B
Sci Pharm; 2010; 78(3):445-50. PubMed ID: 21179357
[TBL] [Abstract][Full Text] [Related]
9. Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane.
Maloney SL; Sullivan DC; Suchting S; Herbert JM; Rabai EM; Nagy Z; Barker J; Sundar S; Bicknell R
Br J Cancer; 2009 Sep; 101(6):957-66. PubMed ID: 19738618
[TBL] [Abstract][Full Text] [Related]
10. Clinical biomarkers of angiogenesis inhibition.
Brown AP; Citrin DE; Camphausen KA
Cancer Metastasis Rev; 2008 Sep; 27(3):415-34. PubMed ID: 18414993
[TBL] [Abstract][Full Text] [Related]
11. Combined razoxane and radiotherapy for melanoma brain metastases. a retrospective analysis.
Rhomberg W; Eiter H; Boehler F; Saely C; Strohal R
J Neurooncol; 2005 Sep; 74(3):295-9. PubMed ID: 16086112
[TBL] [Abstract][Full Text] [Related]
12. Anti-proliferative effects, cell cycle G2/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines.
Lu DY; Huang M; Xu CH; Yang WY; Hu CX; Lin LP; Tong LJ; Li MH; Lu W; Zhang XW; Ding J
BMC Pharmacol; 2005 Jun; 5():11. PubMed ID: 15963241
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo.
Lu DY; Xu B; Ding J
BMC Pharmacol; 2004 Dec; 4():32. PubMed ID: 15617579
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma.
Deplanque G; Madhusudan S; Jones PH; Wellmann S; Christodoulos K; Talbot DC; Ganesan TS; Blann A; Harris AL
Br J Cancer; 2004 Nov; 91(9):1645-50. PubMed ID: 15354209
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.
Colburn WA; Lee JW
Clin Pharmacokinet; 2003; 42(12):997-1022. PubMed ID: 12959633
[TBL] [Abstract][Full Text] [Related]
16. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane.
Anderson H; Yap JT; Wells P; Miller MP; Propper D; Price P; Harris AL
Br J Cancer; 2003 Jul; 89(2):262-7. PubMed ID: 12865914
[TBL] [Abstract][Full Text] [Related]
17. Surrogate markers in antiangiogenesis clinical trials.
Davis DW; McConkey DJ; Abbruzzese JL; Herbst RS
Br J Cancer; 2003 Jul; 89(1):8-14. PubMed ID: 12838293
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
[TBL] [Abstract][Full Text] [Related]
19. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
